4-imidazo[1,2-a]pyridin-2-ylbenzaldehyde | 118000-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-imidazo[1,2-a]pyridin-2-ylbenzaldehyde
• CAS: 118000-48-9
• 化学式: C₁₄H₁₀N₂O
• 分子量: 222.246
• InChiKey: MEDHSOWGQJBYSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-imidazo[1,2-a]pyridin-2-ylbenzaldehyde 在 盐酸 、 正丁基锂 作用下， 以 乙醇 、 硝基苯 为溶剂， 反应 22.25h， 生成
  参考文献：
  名称：

  Bis-Cationic Heteroaromatics as Macrofilaricides:  Synthesis of Bis-Amidine and Bis-Guanylhydrazone Derivatives of Substituted Imidazo[1,2-a]pyridines

  摘要：

  A series of guanylhydrazone, amidine, and hydrazone derivatives of 2-phenylimidazo[1,2-a]pyridine have been prepared and evaluated for macrofilarial activity against Acanthocheilonema viteae and Brugia pahangi in jirds. Compounds with 4',6-bis-substitution by cyclic guanylhydrazone groups show activity. 4',6-Bis-amidines show some activity but are more toxic; 4'- or 6-monosubstituted compounds are inactive. 2,6-Bis-substituted compounds lacking the phenyl ring are inactive. 4',6-Bis-substituted compounds having additional double bonds inserted between the heterocyclic ring and the phenyl ring or between the substituent and the ring system show reduced activity.

  DOI：

  10.1021/jm9803368
• 作为产物：
  描述：

  4-咪唑并[1,2-a]吡啶-2-苯甲腈 在 二异丁基氢化铝 作用下， 以 正己烷 、 甲苯 为溶剂， 反应 1.0h， 以89%的产率得到4-imidazo[1,2-a]pyridin-2-ylbenzaldehyde
  参考文献：
  名称：

  2-芳基和2-芳氧基甲基咪唑并[1,2- a ]吡啶的制备及相关化合物

  摘要：

  一系列取代的2-芳基咪唑并[1,2-α]吡啶已被制备，其中多种取代基被引入在苯环的4'位和在3，5的，6或7位杂环。大多数实例在4'-位具有乙酰氨基，溴，氰基或甲酰基取代基。还已经制备了类似的咪唑并[ 2，1- b ]噻唑和咪唑并[1,2- a ]嘧啶。制备了由咪唑的4'-甲酰基苯氧基甲基衍生物，吡啶，噻唑，苯并咪唑和环取代的咪唑并[1,2- a ]吡啶的三个位置异构体组成的另一系列化合物。还制备了咪唑和咪唑并[1,2- a ]吡啶的2-（4'-甲酰基苯基乙烯基）衍生物。

  DOI：

  10.1002/jhet.5570250119

文献信息

• Preparation of 2-aryl and 2-aryloxymethyl imidazo[1,2-<i>a</i>]pyridines and related compounds
  作者：Richard J. Sundberg、D. J. Dahlhausen、G. Manikumar、B. Mavunkel、Atanu Biswas、V. Srinivasan、Fred King、Philip Waid

  DOI：10.1002/jhet.5570250119

  日期：1988.1

  A series of substituted 2-aryl imidazo[1,2-a]pyridines has been prepared in which a variety of substituents are introduced on the 4′-position of the phenyl ring and on the 3, 5, 6 or 7 position of the heterocyclic ring. Most examples have acetamido, bromo, cyano, or formyl substituents at the 4′-position. Analogous imidazo-[2,1-b]fhiazoles and imidazo[1,2-a]pyrimidines have also been prepared. Another

  一系列取代的2-芳基咪唑并[1,2-α]吡啶已被制备，其中多种取代基被引入在苯环的4'位和在3，5的，6或7位杂环。大多数实例在4'-位具有乙酰氨基，溴，氰基或甲酰基取代基。还已经制备了类似的咪唑并[ 2，1- b ]噻唑和咪唑并[1,2- a ]嘧啶。制备了由咪唑的4'-甲酰基苯氧基甲基衍生物，吡啶，噻唑，苯并咪唑和环取代的咪唑并[1,2- a ]吡啶的三个位置异构体组成的另一系列化合物。还制备了咪唑和咪唑并[1,2- a ]吡啶的2-（4'-甲酰基苯基乙烯基）衍生物。
• [EN] FUSED IMIDAZOLES FOR CANCER TREATMENT<br/>[FR] IMIDAZOLES FUSIONNÉS POUR LE TRAITEMENT DU CANCER
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2009021990A1

  公开（公告）日：2009-02-19

  Compounds of Formula (I), a tautomer or stereoisomer thereof, or a salt thereof,wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibi tors of the Pi3K/Akt pathway.

  式(I)的化合物，其互变异构体或立体异构体，或其盐，其中环B和与其融合的咪唑，R4、R6和R7的含义如描述和权利要求中所述，是Pi3K/Akt途径的有效抑制剂。
• FUSED BICYCLIC IMIDAZOLES
  申请人：HOLDER Swen

  公开号：US20090156604A1

  公开（公告）日：2009-06-18

  Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

  式(I)的化合物或其互变异构体或立体异构体，或其盐，其中环B和其融合的咪唑环，R4，R6和R7的含义如描述和权利要求中所述，是Pi3K/Akt途径的有效抑制剂。
• Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
  申请人：Fujifilm Ri Pharma Co., Ltd.

  公开号：US08022075B2

  公开（公告）日：2011-09-20

  To provide a diagnostic drug which binds specifically to an amyloid aggregate and/or an amyloid deposit, to thereby realize imaging and quantification of a disease caused by amyloid aggregation and/or deposition. The invention provides a compound represented by formula (1): (wherein X1 represents an optionally substituted bicyclic heterocyclic group; X2 represents a hydrogen atom, a halogen atom, or a chelate-forming group; ring A represents a benzene ring or a pyridine ring; and ring B represents an optionally substituted 5-membered aromatic heterocyclic group which is bonded to the benzene ring or the pyridine ring via a carbon atom of ring B), a salt thereof, a solvate of any of these, or a transition metal coordination compound of any of these, and a diagnostic, preventive, or therapeutic drug containing the same.

  提供一种特异性结合到淀粉样聚集体和/或淀粉样沉积物的诊断性药物，从而实现淀粉样聚集和/或沉积引起的疾病的成像和定量。本发明提供了由式（1）表示的化合物：（其中X1代表可选取代的双环杂环基；X2代表氢原子，卤素原子或螯合形成基团；环A代表苯环或吡啶环；环B代表可选取代的5-成员芳香杂环基，通过环B的碳原子与苯环或吡啶环连接），其盐，任何这些的溶剂化合物或过渡金属配合物，以及含有该化合物的诊断性、预防性或治疗性药物。
• Fused bicyclic imidazoles
  申请人：Hölder Swen

  公开号：US08592591B2

  公开（公告）日：2013-11-26

  Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

  式(I)的化合物或其互变异构体或盐，其中环B和与其融合的咪唑，R4，R6和R7的含义如说明书和权利要求所述，是有效的Pi3K / Akt途径的抑制剂。